288eTiP A multicenter, open-label, first-in-human study of TYRA-430 in advanced hepatocellular carcinoma and other solid tumors with activating FGF/FGFR pathway aberrations (SURF431)
Love Goyal(The Christie NHS Foundation Trust), A. Zalutskaya(Structural Analytics (United States)), Alexander S. Vogel(Ontario Institute for Cancer Research), Erik T. Goluboff(Albert Einstein College of Medicine), Raed Moh’d Taiseer Al-Rajabi(The University of Kansas Cancer Center), İbrahim Halil Şahin(University of Pittsburgh), V. Subbiah(Sarah Cannon), T. Burn, Christine Lihou(Structural Analytics (United States)), M. Yarchoan(Sidney Kimmel Cancer Center), Xin Huang(Lineage Cell Therapeutics (United States)), S. Pierpont(Opotek (United States))
Cited by 0
Related Papers
Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer
|New England Journal of Medicine|2018|1.3k
Randomized Phase III KEYNOTE-181 Study of Pembrolizumab Versus Chemotherapy in Advanced Esophageal Cancer
|Journal of Clinical Oncology|2020|1.2k
Efficacy of Selpercatinib in <i>RET</i> Fusion–Positive Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2020|835
Efficacy of Selpercatinib in <i>RET</i> -Altered Thyroid Cancers
|New England Journal of Medicine|2020|766
Immune checkpoint inhibitors for the treatment of MSI-H/MMR-D colorectal cancer and a perspective on resistance mechanisms
|British Journal of Cancer|2019|409